The integration of obesity recognition into routine clinical practice has taken a significant step forward with the introduction of a new validated process measure designed to identify patients who meet body mass index (BMI) criteria for obesity but remain undiagnosed within electronic health records (EHR). Published in the Journal of Clinical Endocrinology & Metabolism (JCEM), the measure represents a collaborative effort between the Endocrine Society and MN Community Measurement (MNCM) to standardize the documentation and management of obesity as a chronic, multifactorial disease. By flagging patients who fall through the cracks of current diagnostic protocols, the measure seeks to align clinical practice with public health priorities, ensuring that obesity is treated with the same clinical rigor as hypertension or type 2 diabetes.
The Evolution of Obesity Management: A Strategic Timeline
The development of this process measure is the culmination of a multi-year initiative that began in 2021. At that time, the Endocrine Society recognized a persistent gap between the clinical definition of obesity and its formal documentation in healthcare systems. While the medical community has increasingly shifted toward viewing obesity through the lens of chronic disease management rather than a simple failure of willpower, the administrative tools used by physicians had not kept pace.
In late 2021, the Endocrine Society partnered with MNCM, an organization specializing in health care quality measurement, to convene a multidisciplinary team of 15 experts. This panel included representatives from endocrinology, internal medicine, family medicine, health policy, and patient advocacy. Throughout 2022 and early 2023, the group conducted a comprehensive landscape review of existing quality measures. They discovered that most current metrics focused on secondary outcomes—such as screening for related comorbidities or providing general education—but failed to address the foundational issue: the absence of a formal diagnosis in the patient’s "problem list" within the EHR.
Following a 30-day public comment period in 2023, the measure was refined and moved into a pilot testing phase. The results of this pilot, involving six large medical groups and nearly 300,000 patients, provided the empirical basis for the recent JCEM publication. This chronology highlights a shift from theoretical advocacy to the implementation of practical, data-driven tools designed for the modern clinical environment.
Quantifying the Diagnosis Gap: Data from the Pilot Study
The pilot testing of the new measure revealed a stark disparity in how obesity is recorded across different healthcare settings. The study analyzed data from 124 clinics and 3,483 providers, covering a total of 295,372 adult patients with a BMI of 30 or higher. The findings underscored a systemic failure to document obesity, particularly in its earlier stages.
According to the study, diagnosis rates varied significantly between medical groups, ranging from a low of 37.6% to a high of 50.8%. This means that in some clinical environments, more than six out of ten patients who met the medical criteria for obesity did not have the condition listed in their formal medical records. The data also revealed a correlation between the severity of obesity and the likelihood of diagnosis. While 35.4% of patients diagnosed with obesity were categorized as Class III (BMI ≥ 40), approximately 61.2% of those with Class I obesity (BMI 30–34.9) lacked a formal diagnosis.
This "Class I gap" is particularly concerning to public health experts because Class I represents the optimal window for early intervention. Without a formal diagnosis, these patients are less likely to receive counseling on lifestyle modifications, referrals to registered dietitians, or discussions regarding pharmacological interventions that could prevent the progression to more severe stages of the disease.
The Clinical Consequences of Administrative Omission
The failure to document obesity is not merely an administrative oversight; it has tangible impacts on patient health outcomes. Amy Rothberg, MD, of the University of Michigan and chair of the measure development group, emphasized that a recorded diagnosis is often the catalyst for treatment. The pilot study tracked weight changes over one year and found a statistically significant difference between patients with and without a documented diagnosis.
Patients who had a formal obesity diagnosis in their EHR lost an average of 0.34 pounds over the course of the year. In contrast, patients who met the BMI criteria but remained undiagnosed gained an average of 1.78 pounds. While these figures may seem modest in isolation, they are critical when viewed against the average American weight trajectory. Dr. Rothberg noted that the typical adult in the U.S. gains between 1.5 and 2.2 pounds annually. By simply providing a formal diagnosis, clinicians were able to halt this upward trend, which represents a major victory in long-term chronic disease management.
Furthermore, the lack of documentation creates a "blind spot" for health systems. Without accurate data, organizations cannot measure the quality of care being provided, track the success of weight-management programs, or identify disparities in how different demographic groups are being treated. The process measure acts as a diagnostic tool for the health system itself, identifying where the "leakage" in patient care is occurring.
Addressing Barriers: From Stigma to "Six Clicks"
The research team identified several barriers that contribute to under-documentation, ranging from systemic EHR design flaws to the social stigma surrounding weight. One practical hurdle identified by Dr. Rothberg is the complexity of EHR interfaces. In many systems, it takes approximately six separate clicks for a physician to move from viewing a patient’s BMI to adding "obesity" to the formal problem list. In a high-pressure clinical environment where primary care visits are often limited to 15 minutes, these administrative hurdles can lead to the omission of the diagnosis in favor of addressing more immediate concerns.
Beyond the technical challenges, there is the persistent issue of weight stigma. Many providers express apprehension about discussing weight with patients, fearing it may damage the therapeutic relationship or cause the patient to feel shamed. However, the authors of the JCEM paper argue that failing to provide a diagnosis can actually reinforce bias. By treating obesity as a formal medical condition rather than a personal failing, clinicians can shift the conversation toward evidence-based treatments and long-term health strategies.
The BMI Debate and the Path Toward Precision
While the new measure relies on BMI as the primary trigger for flagging undiagnosed patients, the authors acknowledge the ongoing debate regarding the metric’s limitations. Critics, including those involved in the recent Lancet Commission on obesity, point out that BMI is an imperfect surrogate for adiposity and does not account for muscle mass, bone density, or the distribution of body fat—all of which influence metabolic risk.
However, the Endocrine Society’s measure prioritizes practicality and scalability. While advanced tools like dual-energy X-ray absorptiometry (DEXA) scans or waist circumference measurements provide more precise data, they are not currently integrated into routine EHR workflows or reimbursed by most insurance plans. BMI remains the most accessible and widely recorded metric in clinical practice. The measure is intended to serve as a starting point, prompting a clinical conversation where a physician can use their judgment to assess the patient’s overall metabolic health.
Strategic Implications for Reimbursement and Advocacy
For endocrinologists and other specialists, the implementation of this process measure is a critical step toward securing adequate reimbursement for obesity care. In the current U.S. healthcare landscape, insurance coverage for obesity treatments—including intensive behavioral therapy and newer GLP-1 receptor agonists—often requires a documented diagnosis of obesity or related comorbidities.
By standardizing the documentation process, the Endocrine Society aims to strengthen its advocacy for equitable access to care. A formal diagnosis in the EHR serves as the legal and clinical "paper trail" necessary for physicians to justify the time and resources spent on weight management. It also provides the data needed to lobby for policy changes, such as the Treat and Reduce Obesity Act (TROA), which seeks to expand Medicare coverage for obesity-related services.
Improving Long-Term Outcomes Through Early Intervention
The ultimate goal of the new process measure is to shift the healthcare system from a reactive model to a proactive one. By identifying obesity early and documenting it consistently, health systems can trigger a cascade of evidence-based interventions before the onset of costly complications like type 2 diabetes, cardiovascular disease, and certain cancers.
The Endocrine Society is currently updating its clinical practice guidelines for both pediatric and pharmacological management of obesity, with a renewed focus on early recognition. As these guidelines are released, the new process measure will provide clinicians with a tangible tool to implement those recommendations in real-time.
As the medical community continues to grapple with the global obesity epidemic, the introduction of this validated process measure offers a clear path forward. It acknowledges that managing obesity requires more than just medical knowledge; it requires the administrative and systemic infrastructure to ensure that every patient is seen, diagnosed, and given the opportunity for treatment. By closing the diagnosis gap, the Endocrine Society and MNCM are helping to ensure that obesity is no longer an overlooked entry on a patient’s medical record, but a recognized priority in the quest for better public health.